"Nationally recognized experts in the treatment of the retina, macula, and vitreous. DOCTORS SERVING THIS LOCATION -Sruthi R. Arepalli, M.D. - Everton L. Arrindell, M.D. - Carl C. Awh, M.D. - Brandon G. Busbee, M.D. - Kenneth P. Moffat, M.D. - Franco M. Recchia, M.D. - David A. Reichstein, M.D. - Eric W. Schneider, M.D. - Peter L. Sonkin, M.D. - Akshay S. Thomas, M.D. - R. Trent Wallace, M.D."

During the past decade, Tennessee Retina, PC conducted 46 clinical trials. In the 10-year time frame, 46 clinical trials started and 13 clinical trials were completed, i.e. on average, 28.3% percent of trials that started reached the finish line to date. In the past 5 years, 28 clinical trials started and 11 clinical trials were completed. i.e. 39.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tennessee Retina, PC" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Genentech, Inc." with 7 trials sponsored, "Kodiak Sciences Inc" with 5 trials sponsored, "Apellis Pharmaceuticals, Inc." with 4 trials sponsored and "Tennessee Retina" with 4 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 26 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tennessee Retina, PC" #1 collaborator was "Genentech, Inc." with 3 trials as a collaborator, "Regeneron Pharmaceuticals" with 3 trials as a collaborator, "Bayer" with 2 trials as a collaborator, "Chugai Pharmaceutical" with 2 trials as a collaborator and "National Eye Institute (NEI)" with 2 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Tennessee Retina, PC" are "Geographic Atrophy" (14 trials), "Macular Degeneration" (8 trials), "Diabetic Macular Edema" (7 trials), "Neovascular Age-related Macular Degeneration" (5 trials) and "Age-related Macular Degeneration" (3 trials). Many other conditions were trialed in "Tennessee Retina, PC" in a lesser frequency.

Most popular intervention types in "Tennessee Retina, PC" are "Drug" (49 trials), "Other" (14 trials), "Biological" (5 trials), "Device" (5 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (14 trials), "Aflibercept" (11 trials), "Faricimab" (8 trials), "KSI-301" (5 trials) and "ranibizumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Tennessee Retina, PC" are 59 trials for "All" genders.

Currently, there are NaN active trials in "Tennessee Retina, PC". undefined are not yet recruiting, 9 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Tennessee Retina, PC, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in Tennessee Retina, PC, 6 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 0 trials that are defined as “Not Applicable".